title: Diabetes Prevention Trial 1: prevalence of GAD and ICA512 (IA-2) autoantibodies by relationship to proband.
abstract: The Diabetes Prevention Trial Type 1 (DPT-1) has recruited relatives of patients with type 1 diabetes throughout the United States and Canada. Of the group screened before June 30, 2000, 71,148 initial screening samples of DPT-1 subjects were tested for GAD65 autoantibodies (GAA) and ICA512 (IA-2) autoantibodies (ICA512AA). Of 71,148 relatives screened, first-degree relatives (4.63%, n = 59,752) had a significantly higher prevalence of autoantibodies than did second-degree relatives (2.61%, n = 9,856) (P < 0.0001 for both autoantibodies). Among first-degree relatives, siblings (5.47%, n = 27,128) had a significantly higher prevalence of autoantibodies than did offspring (3.98%, n = 17,063) and parents (3.88%, n = 15,561) (P < 0.0001 for both autoantibodies). Among offspring, the offspring (n = 105) of both parents with diabetes had twice (8.57%) the prevalence of autoantibodies than did the offspring (n = 16,901) of a single diabetic parent (3.96%). Interestingly, the offspring (n = 8,777) of diabetic fathers had a significantly higher prevalence of autoantibodies than did the offspring (n = 8,124) of diabetic mothers, but only among those aged 10-30 years (P < 0.0001). We conclude that the prevalence of anti-islet cell autoantibodies is affected by multiple levels of relationship to the proband.
authors.affiliation: Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
authors.forename: Liping
authors.initials: L
authors.lastname: Yu
authors.forename: David D
authors.initials: DD
authors.lastname: Cuthbertson
authors.forename: George S
authors.initials: GS
authors.lastname: Eisenbarth
authors.forename: Jeffery P
authors.initials: JP
authors.lastname: Krischer
mesh_terms: D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000032:analysis* / Q000276:immunology; D002170:Canada; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000517:prevention & control; D005260:Female; D005968:Glutamate Decarboxylase / Q000276:immunology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007527:Isoenzymes / Q000276:immunology*; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010375:Pedigree; D014481:United States
chemical_list: D001323:Autoantibodies; C096322:ICA512 autoantibody; D007527:Isoenzymes; D005968:Glutamate Decarboxylase; C401141:glutamate decarboxylase 2